BCAX · Categories · Coverage
BCAX - Analyst coverage initiated
Bicara Therapeutics Inc. (BCAX) analyst coverage initiated - real-time wire coverage filtered to Coverage only.
Recent Coverage for BCAX
- Guggenheim initiated coverage on Bicara Therapeutics with a new price targetGuggenheim initiated coverage of Bicara Therapeutics with a rating of Buy and set a new price target of $42.00
- BofA Securities initiated coverage on Bicara Therapeutics with a new price targetBofA Securities initiated coverage of Bicara Therapeutics with a rating of Buy and set a new price target of $35.00
- Citizens JMP initiated coverage on Bicara Therapeutics with a new price targetCitizens JMP initiated coverage of Bicara Therapeutics with a rating of Mkt Perform and set a new price target of $31.00
- BTIG Research initiated coverage on Bicara Therapeutics with a new price targetBTIG Research initiated coverage of Bicara Therapeutics with a rating of Buy and set a new price target of $28.00
- Mizuho initiated coverage on Bicara Therapeutics with a new price targetMizuho initiated coverage of Bicara Therapeutics with a rating of Neutral and set a new price target of $18.00
- Piper Sandler initiated coverage on Bicara Therapeutics with a new price targetPiper Sandler initiated coverage of Bicara Therapeutics with a rating of Overweight and set a new price target of $36.00
- Wells Fargo initiated coverage on Bicara Therapeutics with a new price targetWells Fargo initiated coverage of Bicara Therapeutics with a rating of Underweight and set a new price target of $8.00
- Wedbush initiated coverage on Bicara Therapeutics with a new price targetWedbush initiated coverage of Bicara Therapeutics with a rating of Outperform and set a new price target of $31.00
- H.C. Wainwright initiated coverage on Bicara Therapeutics with a new price targetH.C. Wainwright initiated coverage of Bicara Therapeutics with a rating of Buy and set a new price target of $42.00
- Rodman & Renshaw initiated coverage on Bicara Therapeutics with a new price targetRodman & Renshaw initiated coverage of Bicara Therapeutics with a rating of Buy and set a new price target of $48.00
- Cantor Fitzgerald initiated coverage on Bicara TherapeuticsCantor Fitzgerald initiated coverage of Bicara Therapeutics with a rating of Overweight
- Morgan Stanley initiated coverage on Bicara Therapeutics with a new price targetMorgan Stanley initiated coverage of Bicara Therapeutics with a rating of Overweight and set a new price target of $35.00
- TD Cowen initiated coverage on Bicara TherapeuticsTD Cowen initiated coverage of Bicara Therapeutics with a rating of Buy
- Stifel initiated coverage on Bicara Therapeutics with a new price targetStifel initiated coverage of Bicara Therapeutics with a rating of Buy and set a new price target of $47.00